Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing